This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -200.00% and 0.22%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals (EYPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 9.09% and 46.69%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals (EYPT) Surges: Stock Moves 7.4% Higher
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -10.00% and 7.83%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 25.00% and 12.19%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Will EyePoint Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in EyePoint.
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 0.00% and -47.82%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will EyePoint Pharmaceuticals (EYPT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 15.38% and 6.82%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals (EYPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -23.08% and -45.55%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will EyePoint Pharmaceuticals (EYPT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 14.29% and 272.82%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: EyePoint Pharmaceuticals (EYPT) Q2 Earnings Expected to Decline
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for EyePoint Pharmaceuticals (EYPT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to EyePoint Pharmaceuticals (EYPT) stock based on the movements in the options market lately.
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -46.15% and -30.57%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Will EyePoint Pharmaceuticals (EYPT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq
by Zacks Equity Research
EyePoint (EYPT) gains an FDA approval for its eye therapy Yutiq to help cure chronic non-infectious uveitis affecting the posterior segment of the eye.
EyePoint Pharmaceuticals (EYPT) Catches Eye: Stock Jumps 6.8%
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Implied Volatility Surging for EyePoint Pharmaceuticals (EYPT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to EyePoint Pharmaceuticals (EYPT) stock based on the movements in the options market lately.
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -111.11% and 6.72%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals (EYPT) Q4 Earnings Preview: What to Know Ahead of the Release
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will EyePoint Pharmaceuticals (EYPT) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in EyePoint Pharmaceuticals, Inc. (EYPT)